HydRegen, an Oxford-based biotechnology company enabling sustainable chemical manufacturing, has secured a £2.6 million investment as part of its latest fundraise, led by Clean Growth Fund, the UK clean-tech venture capital fund.
Following HydRegen’s spin out from the University of Oxford in 2021, Dr Holly Reeve (CEO) and Dr Sarah Cleary (Chief Scientific Officer) have been focused on pioneering the production of bio-based catalysts that enable cleaner, safer and more energy-efficient manufacturing processes for the global pharmaceutical and chemicals industries.
In these applications, HydRegen aims to deploy its innovative biotechnologies to enable the transition to a low carbon economy with more sustainable and efficient chemical manufacturing processes: a key reason for Clean Growth Fund’s investment.
The new investment from Clean Growth Fund, alongside a group of existing investors, will support the commercial development and deployment of HydRegen’s technologies through the next 18 months. HydRegen plans to license its technology to companies manufacturing pharmaceutical and chemical products around the world.